Table 4. Ongoing Randomized Phase III Trials of Adjuvant Immunotherapy in Early-Stage and Locally-Advanced NSCLC.

	Eligible patients	Intervention	Estimated enrolment	Primary endpoint
ANVIL NCT02595944	IB-IIIA	Arm A: Surgery→CT→Nivolumab 1 year Arm B: Surgery→CT→Observation.	n=903	DFS OS
IMpower010 NCT02486718	II, IIIA, select IIIB	Arm A: Surgery→Platinum doublet×4 cycles→Atezolizumab×16 cycles. Arm B: Surgery→Platinum doublet×4 cycles→Observation.	n=1280	DFS OS
KEYNOTE 091-PEARLS NCT02504372	IB/II-IIIA	Arm A: Surgery→±CT→Pembrolizumab 1 year Arm B: Surgeryi±CT→Placebo 1 year	n=1080	DFS
BR-31 NCT02273375	IB-IIIA	Arm A: Surgery→±CT→Durvalumab 1 year Arm B: Surgery→±CT→Placebo 1 year	n=1360	DFS
CANOPY-A NCT03447769	II -IIIA and IIIB (T>5cm N2)	Arm A: Surgery→±CT→Canakinumab×18 cycles. Arm B: Surgery→±CT→Placebo 18 cycles.	n=1500	DFS

CT: Chemotherapy, RT: Radiotherapy, DFS: Disease-free survival, OS: Overall survival